Cystic Fibrosis Research Translation Center
Pilot and Feasibility Program

DUE JANUARY 17, 2018

FOR FURTHER INFORMATION CONTACT:
Dr. Bonnie Ramsey, Professor, Pediatrics (206-987-5725) bonnie.ramsey@seattlechildrens.org
Dr. Pete Greenberg, Professor, Microbiology (206-616-2881) epgreen@u.washington.edu
Dr. Pradeep Singh, Professor, Microbiology (206-221-7151) singhpr@u.washington.edu

The NIH P30 Cystic Fibrosis Research Translation Center (CFRTC) is seeking applications for Pilot and Feasibility Studies focused on development and/or translation of promising laboratory findings that may lead to novel therapies for individuals with cystic fibrosis (CF).

Pilot and Feasibility applications will be awarded starting in June 2018 for up to 2 years at $40,000 - $75,000 direct costs per year. Investigators eligible for pilot and feasibility funding generally fall into three categories: (1) new investigators without current or past NIH research support as a principal investigator; (2) established investigators with no previous work in CF who wish to apply their expertise to a problem in this area; and (3) established investigators who propose testing innovative ideas that represent clear departure from ongoing research interests. It is expected that the majority of the investigators will fall into the first category. **All eligible investigators, however, must have faculty appointments and be independent investigators. Postdoctoral fellows or their equivalents are not eligible.**

Each pilot and feasibility study proposal should state clearly the justification for eligibility of the investigator under one of the above three criteria. **Pilot Projects should make use of the resources provided by one or more P30 Cores**. Please contact the relevant Core Director(s) to discuss your application prior to submission.

Examples of relevant research topics are:

1. Promote and expedite the translation of basic laboratory observations into a) better understanding of clinical disease b) improved diagnostic tools for assessing early disease manifestations in CF and/or c) new therapeutic approaches for treating gastrointestinal, hepatic, metabolic (including CF related diabetes mellitus) and lung disease in CF.
2. Better understand the impact of bacterial genetic factors and phenotypic characteristics on progression of CF lung disease and GI health and utilize these findings to develop improved therapeutic approaches.
3. Better understand host inflammatory responses to bacterial infection to optimize anti-inflammatory and anti-infective approaches.
4. Better understand early infection in infants diagnosed with CF through newborn screening.

Applicants should use PHS 398 forms and Guidelines for completing this application. Research plans are limited to **5 pages** not including references. Applications must be submitted by **January 17, 2018** to Donna Crist at donna.crist@seattlechildrens.org.

Signatures from UW/SCRI institutional officials are **NOT** required for the application. All other affiliate institutions should provide a signed face pages or LOI. IRB and/or IACUC approvals will be required prior to funding.

UW Medicine
SCHOOL OF MEDICINE

Seattle Children's
HOSPITAL • RESEARCH • FOUNDATION